Salvage therapy for locally recurrent prostate cancer after external beam radiotherapy

Current Treatment Options in Oncology

Volumn 5, Issue 5, 2004, Pages 357-365

  Stephenson, Andrew J ^b   Scardino, Peter T ^b   Bianco Jr , Fernando J ^b   Eastham, James A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

BEAM THERAPY; BRACHYTHERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CRYOTHERAPY; DISEASE COURSE; EARLY DIAGNOSIS; ERECTILE DYSFUNCTION; HUMAN; MALE; MORBIDITY; PERIOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RADIATION BEAM; REVIEW; SALVAGE THERAPY; SURGICAL TECHNIQUE; URINE INCONTINENCE;

EID: 8344254346     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-004-0026-2     Document Type: Review

References (50)

1. Jemal A, Tiwari RC, Murray T, et al.: Cancer statistics, 2004. CA Cancer J Clin 2004, 54:8-29.
2. Lee WR, Moughan J, Owen JB, Zelefsky MJ: The 1999 patterns of care study of radiotherapy in localized prostate carcinoma: a comprehensive survey of prostate brachytherapy in the United States. Cancer 2003, 98:1987-1994.
3. Brandeis J, Pashos CL, Henning JM, Litwin MS: A nationwide charge comparison of the principal treatments for early stage prostate carcinoma. Cancer 2000, 89:1792-1799.
4. Shipley WU, Thames HD, Sandler HM, et al.: Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. Jama 1999, 281:1598-1604.
5. Kuban DA, Thames HD, Levy LB, et al.: Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 2003, 57:915-928.
6. Lee WR, Hanks GE, Hanlon A: Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. J Clin Oncol 1997, 15 230-238.
7. Pollack A, Zagars GK, Kavadi VS: Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer Cancer 1994, 74:670-678.
8. Pinover WH, Horwitz EM, Hanlon AL, et al.: Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy. Cancer 2003, 97:1127-1133.
9. D'Amico AV, Cote K, Loffredo M, et al.: Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002, 20:4567-4573.
10. Sandler HM, Dunn RL, McLaughlin PW, et al.: Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys 2000, 48:629-633.
11. Grossfeld GD, Li YP, Lubeck DP, et al.: Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor. J Urol 2002, 168:530-535.
12. Zelefsky MJ, Leibel SA, Gaudin PB, et al.: Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998, 41:491-500.
13. Zagars GK, Pollack A, von Eschenbach AC: Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen. Int J Radiat Oncol Biol Phys 1995, 33:23-35.
14. Fuks Z, Leibel SA, Wallner KE, et al.: The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 1251 implantation. Int J Radiat Oncol Biol Phys 1991, 21:537-547.
15. Holzman M, Carlton CE Jr, Scardino PT: The frequency and morbidity of local tumor recurrence after definitive radiotherapy for stage C prostate cancer. J Urol 1991, 146:1578-1582.
16. Schellhammer PF, Kuban DA, el-Mahdi AM: Treatment of clinical local failure after radiation therapy for prostate carcinoma. J Urol 1993, 150:1851-1855.
17. Pound CR, Partin AW, Eisenberger MA, et al.: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281:1591-1597.
18. Crook JM, Perry GA, Robertson S, Esche BA: Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology 1995, 45:624-631; discussion 631-632.
19. Cox JD, Gallagher MJ, Hammond EH, et al.: Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 1999, 17:1155.
20. Hanlon AL, Pinover WH, Horwitz EM, Hanks GE: Patterns and fate of PSA bouncing following 3D-CRT. Int J Radiat Oncol Biol Phys 2001, 50:845-849.
21. Rosser CJ, Kuban DA, Levy LB, et al.: Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. J Urol 2002, 168 2001-2005.
22. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997, 37:1035-1041.
23. Pollack A, Zagars GK, Antolak JA, et al.: Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys 2002, 54 677-685.
24. Scardino PT, Frankel JM, Wheeler TM, et al.: The prognostic significance of post-irradiation biopsy results in patients with prostatic cancer. J Urol 1986, 135:510-516.
25. Eastham JA, Scardino PT: Salvage radical prostatectomy: improving outcome after failed radiation therapy. Contemp Urol 2004, In press.
26. Pontes JE, Montie J, Klein E, Huben R: Salvage surgery for radiation failure in prostate cancer. Cancer 1993, 71 976-980.
27. Rogers E, Ohori M, Kassabian VS, et al.: Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. J Urol 1995, 153:104-110.
28. Brenner PC, Russo P, Wood DP, et al.: Salvage radical prostatectomy in the management of locally recurrent prostate cancer after 125I implantation. Br J Urol 1995, 75:44-47.
29. Link P, Freiha FS: Radical prostatectomy after definitive radiation therapy for prostate cancer. Urology 1991, 37 189-192.
30. Amling CL, Lerner SE, Martin SK, et al.: Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer. J Urol 1999, 161:857-862; discussion 862-863.
31. Stein A, Smith RB, deKernion JB: Salvage radical prostatectomy after failure of curative radiotherapy for adenocarcinoma of prostate. Urology 1992, 40:197-200.
32. Gheiler EL, Tefilli MV, Tiguert R, et al.: Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. Urology 1998, 51:789-795.
33. Moul JW, Paulson DF: The role of radical surgery in the management of radiation recurrent and large volume prostate cancer. Cancer 1991, 68:1265-1271.
34. Lerner SE, Blute ML, Zincke H: Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer. J Urol 1995, 154:1103-1109.
35. Stephenson AJ, Scardino PT, Bianco FJ Jr, et al.: Morbidity and functional outcomes of salvage radical prostatectomy for radiorecurrent prostate cancer. J Urol 2004, In Press.
36. Dillioglugil O, Leibman BD, Leibman NS, et al.: Risk factors for complications and morbidity after radical retropubic prostatectomy. J Urol 1997, 157:1760-1767.
37. Vallancien G, Gupta R, Cathelineau X, et al.: Initial results of salvage laparoscopic radical prostatectomy after radiation failure. J Urol 2003, 170:1838-1840.
38. Gheiler EL, Wood DP Jr, Montie JE, Pontes JE: Orthotopic urinary diversion is a viable option in patients undergoing salvage cystoprostatectomy for recurrent prostate cancer after definitive radiation therapy. Urology 1997, 50:580-584.
39. Ahlering TE, Lieskovsky G, Skinner DG: Salvage surgery plus androgen deprivation for radioresistant prostatic adenocarcinoma. J Urol 1992, 147:900-902.
40. Pisters LL, English SF, Scott SM, et al.: Salvage prostatectomy with continent catheterizable urinary reconstruction: a novel approach to recurrent prostate cancer after radiation therapy. J Urol 2000, 163:1771-1774.
41. Izawa JI, Perrotte P, Greene GF, et al.: Local tumor control with salvage cryotherapy for locally recurrent prostate cancer after external beam radiotherapy. J Urol 2001, 165 867-870.
42. Izawa JI, Madsen LT, Scott SM, et al.: Salvage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcome. J Clin Oncol 2002, 20 2664-2671.
43. Ghafar MA, Johnson CW, De La Taille A, et al.: Salvage cryotherapy using an argon based system for locally recurrent prostate cancer after radiation therapy: the Columbia experience. J Urol 2001, 166:1333-1337; discussion 1337-1338.
44. Chin JL, Pautler SE, Mouraviev V, et al.: Results of salvage cryoablation of the prostate after radiation: identifying predictors of treatment failure and complications. J Urol 2001, 165:1937-1941; discussion 1941-1932.
45. Leibovich BC, Izawa J, Zincke H, et al.: Recurrent prostate cancer after radiation therapy: salvage prostatectomy versus salvage cryosurgery. J Urol 2001, 165:1595A.
46. Perrotte P, Litwin MS, McGuire EJ, et al.: Quality of life after salvage cryotherapy: the impact of treatment parameters. J Urol 1999, 162:398-402.
47. Sylvester J, Grimm P, Blasco J, et al.: The role of androgen ablation in patients with biochemical or local failure after definitive radiation therapy: a survey of practice patterns of urologists and radiation oncologists in the United States. Urology 2001, 58:65-70.
48. Beyer DC: Permanent brachytherapy as salvage treatment for recurrent prostate cancer. Urology 1999, 54:880-883.
49. Grado GL, Collins JM, Kriegshauser JS, et al.: Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999, 53:2-10.
50. Moul JW: Prostate specific antigen only progression of prostate cancer. J Urol 2000, 163:1632-1642.